Patent ID: 8828966

Claim:
A method of treating age-related macular degeneration (AMD) in a patient subject to or symptomatic of age-related macular degeneration (AMD), the method comprising administering to a patient at least one P2X7 receptor antagonist selected from the group consisting of A438079, (3-[[5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl]methy]pyridine hydrochloride salt, C13H9C12N5•HC1, BBG for ophthalmic use, C47H48N3NaO7S2,Acid blue 90, Coomassie® Brilliant Blue G, A740003(18/40 nM), AZ-10606120(19/1.4nM); AZ-1645373(6 nM human); KN-62(15 nM human), A-839977, A-847227, AZ-116453743, GSK314181A, AFC-5128, AZD-9056, CE-224535, AF-4025, EVT 401, MRS 2159, MRS2306 and MRS 2540, to inhibit P2X7 receptor activity, thereby acidifying lysosomal pH (pH L ) in the retinal pigment epithelium (RPE) cell(s) of the patient's eyes.